Despite the death of its golden goose, AbbVie expects to achieve high single-digit compound annual sales growth to the end of ...

AbbVie is a Dividend King that's quickly moving past reliance on Humira. Enbridge shouldn't be affected by potential Canadian ...

AbbVie made a change atop its board of directors, naming CEO Robert Michael as chairman on Friday morning. The pharma giant announced that Michael will succeed Richard A. Gonzalez, the former CEO of ...

Invest in essential sectors like consumer staples and energy to beat inflation. See why these stocks offer reliable dividends ...

Yet, their place and cost remain fairly misunderstood. For over a decade, Humira has been the highest-grossing drug in the world, bringing in some $21 billion for manufacturer AbbVie in 2021.

February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three ...

Alvotech has developed a biosimilar of Humira called AVT02, the first-filed biosimilar drug equal in strength to Humira’s latest formulation, which AbbVie markets as a high-concentration, pain ...

Just as Andrew Witty of UnitedHealth Group did in a call with investors last month, CVS Health’s CEO David Joyner defended ...

Last year was a pivotal year for the pharmaceutical industry. Under the IRA’s Medicare Drug Price Negotiation Program (the ...

That’s why one of the most closely watched elements of a company’s earnings report is the guidance it gives for the next quarter or year. We’re still midway through the current earnings season, but ...

AbbVie's underlying business remains strong, and so does its dividend program. The company is a Dividend King with 52 ...